Quantcast
Last updated on April 18, 2014 at 13:47 EDT

Latest Design of experiments Stories

2014-04-17 12:29:28

LONDON, April 17, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Brain Cancer Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/drug_discovery/brain_cancer_global_clinical_trials_review_h1_2014.htmlBrain Cancer Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Brain Cancer Global Clinical Trials Review, H1, 2014" provides data on the Brain Cancer clinical trial scenario. This report...

2014-04-17 00:21:10

DUBLIN, April 17, 2014 /PRNewswire/ -- Heart Metabolics Limited, a new Irish biotechnology company focused on development of drugs for cardio-metabolic diseases, has announced the completion of a $20 million Series A financing from venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill. The proceeds from this financing have supported Heart Metabolics Limited in acquiring a Phase 3-ready drug candidate and related preclinical drug...

2014-04-16 23:09:48

New webinar will focus on how to handle and prevent missing data to improve clinical trial data credibility. The live discussion takes place on Friday, May 2, 2014 at 10:00am EDT (15:00 UK BST/ GMT +1). Toronto, Canada (PRWEB) April 16, 2014 Missing data is common in most clinical trials because some subjects withdraw from the trial before the crucial final measurements. Without those final measurements, our picture of the new treatment is imperfect, and it could actually be wrong. What...

2014-04-16 08:34:21

Clinical Results Open Significant Market Opportunity for BioElectronics Corp. FREDERICK, Md., April 16, 2014 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices, announced reports on preliminary results of a randomized, double blind, placebo controlled trial on osteoarthritis of the knee (knee pain) using ActiPatch® Therapy. An abstract on the interim analysis of the osteoarthritis (OA) knee pain study has been accepted by...

2014-04-16 00:21:06

TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American...

2014-04-11 00:21:52

-SVR(12) rates of 96 percent were achieved in both SAPPHIRE-I (new to therapy) and SAPPHIRE-II (treatment-experienced with pegylated interferon and ribavirin) in adult patients with genotype 1 chronic hepatitis C virus infection LONDON, April 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that detailed results from its phase III pivotal study, SAPPHIRE-I, will be presented today at the International Liver Congress(TM) (ILC) 2014 and featured in the ILC press conference....

2014-04-10 10:13:27

Meta-analysis finds relationship improvement has beneficial effects similar to some common treatments A meta-analysis of studies that investigated measures designed to improve health professionals' interactions with patients confirms that such efforts can produce health effects just as beneficial as taking a daily aspirin to prevent heart attack. In contrast to previous such reviews, the current report from the Empathy and Relational Science Program at Massachusetts General Hospital (MGH)...

2014-04-07 12:34:11

LONDON, April 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Ventricular Arrhythmia Global Clinical Trials Review, H2, 2013 Ventricular Arrhythmia Global Clinical Trials Review, H2, 2013 SummaryGlobalData's clinical trial report, "Ventricular Arrhythmia Global Clinical Trials Review, H2, 2013" provides data on the Ventricular Arrhythmia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on...

2014-04-07 08:29:21

TORONTO, April 7, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) provided an update on the development of its drug candidates and plans for future growth. The addition of the neuropsychiatric drug candidate ELND005 has broadened the Company's development pipeline with an un-partnered late-stage clinical asset, coupled with Transition's core strategy of advancing assets acquired from pharmaceutical partners. From a...

2014-04-04 23:34:34

Innovative Adaptive Designs Increase Trial Flexibility and Efficiency, Generating Significant Ethical and Economic Advantages Reston, Virginia (PRWEB) April 03, 2014 Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency, and productivity of product development, will present emerging strategies for using adaptive trial designs to improve the success...